A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"
Abroad (travel likely)RecruitingPHASE2
Conditions
Phase 2 · Radiotherapy-Induced Immune Priming · Elranatamab · Relapsed Refractory Multiple Myeloma (RRMM) · Extramedullary Disease in Multiple Myeloma · Paramedullary Disease · PMD
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
MD Anderson Cancer Center, Houston, Texas, United States
Contact: Principal Investigator (Christine Ye, MD)
Study leads
Christine Ye, MD
Principal Investigator
M.D. Anderson Cancer Center